#1 Clinical Trials Search in Europe

3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid

This article explores the ongoing clinical trials of LB-100, a new drug being investigated for its potential in treating various types of cancer. LB-100, chemically known as 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid, is being studied in combination with other cancer treatments for colorectal cancer, soft tissue sarcomas, and other advanced cancers. These trials aim to determine the safety, effectiveness, and optimal dosing of LB-100 when used alongside established cancer therapies.

Table of Contents

What is LB-100?

LB-100 is a new drug being studied for the treatment of various types of cancer. Its scientific name is 3-(4-methylpiperazine-1-carbonyl)-7-oxabiclo[2.2.1]heptane-2-carboxylic acid[1]. It is described as the “first of a novel class of therapeutic agents” and an “enhancer of chemotherapy and immunotherapy”[2]. This means that LB-100 is a unique drug that works differently from existing cancer treatments and may help make other cancer therapies work better.

How does LB-100 work?

LB-100 is known as a PP2A inhibitor[1]. PP2A stands for Protein Phosphatase 2A, which is an enzyme in our cells that plays a role in regulating cell growth and division. By inhibiting PP2A, LB-100 may be able to interfere with cancer cell growth and make cancer cells more vulnerable to other treatments.

What types of cancer is LB-100 being studied for?

Based on the clinical trials information provided, LB-100 is being studied for several types of cancer:

  • Colorectal cancer: This is cancer that starts in the colon or rectum[1][3].
  • Soft tissue sarcomas: These are cancers that develop in soft tissues like muscles, fat, and blood vessels. Specific types being studied include:
    • Undifferentiated pleomorphic sarcoma
    • Leiomyosarcoma
    • Myxoid liposarcoma
    • Synovial sarcoma
    • And several others[2]

Clinical trials involving LB-100

There are several clinical trials currently studying LB-100:

  1. The CoLBAt Trial: This study is testing LB-100 in combination with a drug called atezolizumab for patients with metastatic colorectal cancer[1].
  2. Soft Tissue Sarcoma Trial: This study is comparing LB-100 plus doxorubicin (a chemotherapy drug) to doxorubicin alone in patients with advanced soft tissue sarcomas[2].
  3. The COLLEE Trial: This study is testing LB-100 in combination with a drug called azenosertib in patients with metastatic colorectal cancer[3].

These trials are in early phases (Phase I/II), which means researchers are still determining the best dose of LB-100 to use and looking at its initial safety and effectiveness.

Potential benefits of LB-100

While it’s important to note that LB-100 is still in the early stages of research, some potential benefits being studied include:

  • Enhancing the effects of other cancer treatments like chemotherapy and immunotherapy[1][2].
  • Potentially improving outcomes for patients with advanced cancers that have limited treatment options[3].
  • Offering a new approach to treating cancer by targeting the PP2A enzyme[1].

Side effects and safety considerations

As LB-100 is still in clinical trials, all of its potential side effects are not yet known. The trials are carefully monitoring patients for any adverse events (side effects). Some things to note:

  • Patients in the trials must have adequate organ function and meet specific health criteria to participate[2][3].
  • There is a particular focus on monitoring heart function in these trials[2].
  • Some trials are looking at the possibility of immune-related side effects when LB-100 is combined with other drugs[1][3].

Conclusion

LB-100 is a promising new drug being studied for various types of cancer, particularly colorectal cancer and soft tissue sarcomas. It works in a unique way by inhibiting the PP2A enzyme and may enhance the effects of other cancer treatments. While the research is still in early stages, LB-100 represents a potential new approach to cancer treatment. As with any experimental treatment, it’s important for patients to discuss the potential risks and benefits with their healthcare team and to understand that more research is needed to fully understand the effectiveness and safety of LB-100.

Trial Name Cancer Type Combination Treatment Primary Objective Key Eligibility Criteria
CoLBAt Trial Metastatic Colorectal Cancer LB-100 + Atezolizumab Determine RP2D of LB-100 with Atezolizumab Microsatellite stable CRC, measurable disease, ECOG 0-1
Soft Tissue Sarcoma Trial Advanced Soft Tissue Sarcomas LB-100 + Doxorubicin Determine MTD and RP2D of LB-100 with Doxorubicin Various sarcoma subtypes, measurable disease, ECOG 0-1
COLLEE Trial Metastatic Colorectal Cancer LB-100 + Azenosertib Determine RP2D of LB-100 with Azenosertib Advanced CRC, measurable disease, ECOG 0-1

FAQ

  • What is LB-100? LB-100 is a novel drug being studied for cancer treatment. It is chemically known as 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid and is classified as a PP2A inhibitor, which means it affects certain cellular processes that may help fight cancer.
  • What types of cancer are being studied with LB-100? The clinical trials are focusing on metastatic colorectal cancer, advanced soft tissue sarcomas, and other types of advanced or metastatic cancers.
  • How is LB-100 being used in these trials? LB-100 is being tested in combination with other cancer treatments. For example, it's being combined with atezolizumab for colorectal cancer, with doxorubicin for soft tissue sarcomas, and with azenosertib for metastatic colorectal cancer.
  • What are the main goals of these clinical trials? The primary goals are to determine the safe and effective dose of LB-100 when combined with other treatments (known as the recommended phase 2 dose or RP2D), to assess its safety and tolerability, and to evaluate its effectiveness in treating cancer.
  • How do patients qualify for these trials? Eligibility varies by trial but generally includes being an adult with a confirmed diagnosis of the specific cancer type being studied, having measurable disease, and meeting certain health criteria. Patients must also provide informed consent and be willing to comply with the study procedures.

Ongoing Clinical Trials on 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid

  • Study of LB-100 and Atezolizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of LB-100 and Azenosertib for Patients with Metastatic Colorectal Cancer

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of LB-100 plus doxorubicin compared to doxorubicin alone in adults with advanced soft tissue sarcomas as first-line treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • LB-100: A novel drug being studied for cancer treatment, chemically known as 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid. It is classified as a PP2A inhibitor.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Colorectal Cancer: Cancer that starts in the colon or rectum, parts of the large intestine.
  • Soft Tissue Sarcoma: A type of cancer that begins in the soft tissues of the body, such as muscle, fat, or blood vessels.
  • RP2D: Recommended Phase 2 Dose – the optimal dose of a drug determined to be safe and effective for further study in larger clinical trials.
  • Atezolizumab: A type of immunotherapy drug used to treat certain types of cancer.
  • Doxorubicin: A chemotherapy drug used to treat various types of cancer.
  • Azenosertib: A drug being studied for cancer treatment, classified as a WEE1 inhibitor.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • RECIST: Response Evaluation Criteria in Solid Tumors – a set of rules used to measure if tumors are responding to treatment.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a dose reduction.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-lb-100-and-atezolizumab-for-patients-with-metastatic-colorectal-cancer/
  2. http://clinicaltrials.eu/trial/study-of-lb-100-and-doxorubicin-for-adults-with-advanced-soft-tissue-sarcomas/
  3. http://clinicaltrials.eu/trial/study-of-lb-100-and-azenosertib-for-patients-with-metastatic-colorectal-cancer/